A recent study suggests that people who stop using popular GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass much more quickly than those who stop traditional diet and exercise regimens.
Published data in a major health publication points out that while overweight individuals frequently drop substantial amounts of their total mass while using the jabs, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"Individuals buying these drugs must be aware of the risk of rapid rebound weight gain when the therapy concludes," stated researcher Dr. Susan Jebb.
Such speed of regain implies a return to starting weight in about 18 months.
Analyzing Therapies
The analysis, which reviewed dozens of studies involving over 9,000 of patients, compared the outcomes of these new drugs with other pills.
Researchers emphasize that individuals who lose weight through diet and exercise typically have a more gradual creep back—perhaps 0.1 kg a month—once they finish.
Understanding the Rapid Rebound
Nutrition scientists propose the mechanism of the injections explains the heightened weight return.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls appetite.
"Sustained high doses of GLP-1 levels far above than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and could diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication results in appetite is no longer kept in check, making overeating much more probable."
An Ongoing Condition?
Medical guidelines recommend the jabs for individuals with weight-linked health risks, alongside recommended lifestyle changes.
A number of clinicians say that, considering the high risk of weight regain, the therapy might need to be long-term.
This perspective is supported by drug manufacturers, who note that the findings "emphasize the long-term nature of excess weight," comparing it to managing diseases like diabetes.
Patient Accounts
Individuals who have come off the medication report a powerful resurgence of hunger.
"It felt as if a switch flipping and I was suddenly starving," recalled an individual.
The struggle is worsened if users have not established lasting dietary or behavioural changes during treatment.
Widespread Adoption
Survey data show that a significant number of adults in the UK have used these injections in the last 12 months, with interest being substantial.
- Use is higher among females than men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic cure and maintained weight loss hinges on integrated lifestyle support.
